<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75572">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01929044</url>
  </required_header>
  <id_info>
    <org_study_id>202.848</org_study_id>
    <nct_id>NCT01929044</nct_id>
  </id_info>
  <brief_title>Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain</brief_title>
  <official_title>A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy of Buscopan® (hyoscine butylbromide) in
      comparison to 654-II (anisodamine)in acute gastric or intestinal spasm-like pain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain intensity difference (PID) from pre-dose baseline at 20 minutes after the first injection.</measure>
    <time_frame>baseline and 20min</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PID from pre-dose baseline at 10, 30, 60 and 120 minutes after the first injection.</measure>
    <time_frame>up to 120min</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy by the patient  at 120 minutes after the first injection using a 4-point rating scale (0=poor; 1=fair; 2=good; 3=very good).</measure>
    <time_frame>120min</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who need the second injection at 20 minutes after the first injection.</measure>
    <time_frame>20min</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">296</enrollment>
  <condition>Intestinal Diseases</condition>
  <arm_group>
    <arm_group_label>Buscopan® (hyoscine butylbromide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>654-II(anisodamine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>654-II (anisodamine)</intervention_name>
    <description>10mg injection</description>
    <arm_group_label>654-II(anisodamine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buscopan® (hyoscine butylbromide)</intervention_name>
    <description>20mg injection</description>
    <arm_group_label>Buscopan® (hyoscine butylbromide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients must sign and date an Informed Consent consistent with International
             Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines and local
             regulation prior to participation in the trial.

          2. Patients must agree to cooperate with all trial evaluations and perform all required
             tasks.

          3. Patients with acute gastric or intestinal spasm-like pain (without severe vomiting
             and surgical acute abdomen).

          4. Male or female patients aged 18 to 70 years.

          5. The pain intensity upon screening is at least point 6 on a 0-10 numerical rating
             scale (NRS).

        Exclusion criteria:

          1. Patients with the following concomitant disease is not eligible for enrollment:

               -  Painful gastric or intestinal spasm of organic origin such as Crohn's disease,
                  ulcerative colitis, lactose intolerance, gastrointestinal perforation, suspected
                  gastrointestinal perforation or peritoneal effusion.

               -  Pain related with malignancy.

               -  Patients with other severe pain states of organic origin.

               -  Mechanical stenosis of the gastrointestinal tract ,megacolin.

               -  Urinary retention associated with mechanical stenosis of urinary tract.

               -  Narrow-angled glaucoma.

               -  Tachyarrhythmia.

               -  Myasthenia gravis.

               -  Meulengracht-Gilbert syndrome.

               -  Known depression or known mental illness, anxiety disturbance.

          2. Patients taking the following concomitant medication within 7 half-life of
             concomitant medication  (the duration from taking concomitant medication to attending
             the trial is less than 7 half-life) are not eligible for enrollment:

               -  Analgesics,

               -  Spasmolytics,

               -  Anticholinergics

               -  Affecting gastrointestinal motility, such as propantheline, metoclopramide,
                  cisapride, loperamide, diphenoxylate, opioid analgesics, antacids and other
                  ulcer treatment

               -  Regular administration of laxatives

               -  Narcotics

               -  Antidepressant treatment or treatment with psychoactive drugs

          3. Pregnancy and/or lactation or planned pregnancy;

          4. Known hypersensitivity to N-butylscopolammonium bromide

          5. Alcohol, or drug abuse.

          6. Simultaneous participating in another clinical trial, or discontinuing from another
             clinical trial before randomization (administration of study medication); moreover,
             in the case of screening failure or premature discontinuing from the trial, repeated
             enrollment is forbidden.

          7. Unwilling to or unable to complete the entire trial procedure according to the
             protocol.

          8. In investigator's opinion, the patient is not proper for the trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>202.848.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202.848.86017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>August 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Anisodamine</mesh_term>
    <mesh_term>Scopolamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
